On July 8, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the validity of a Janssen patent, finding that Teva did not meet its burden to prove obviousness.  In so doing, the Federal Circuit provided direction regarding how the overlapping range presumption should be applied and the need for a fact-specific analysis in obviousness challenges.